Here are seven highlights:
1. The company saw net sales of $108.9 million, reflecting a 4.7 percent increase over the same period the year prior.
2. Biologic sales jumped 9.9 percent to $15.7 million, compared to the second quarter of 2016.
3. Orthofix’s spine fixation sales hit $21.4 million, a 17.1 percent increase over the second quarter of 2016.
4. The company’s gross profit increased to $85.8 million over the year prior.
5. Net income from continuing operations hit $4.7 million, or $0.26 per share.
6. Orthofix’s EBITDA was $14 million in the second quarter of 2017, up from $2.6 million in the same period the year prior.
7. The company’s cash and cash equivalents were $44.3 million as of June 30.
More articles on devices:
K2M, Smith & Nephew & more: 9 device company mergers, acquisitions and agreements
RTI Surgical reports $72.1M in Q2 revenue: 5 highlights
DePuy Synthes & Medical Enterprises Distribution to co-market automated THA technology: 6 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
